BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 12539169)

  • 21. Molecular targeting of VHL gene pathway in clear cell kidney cancer.
    Linehan WM
    J Urol; 2003 Aug; 170(2 Pt 1):593-4. PubMed ID: 12853837
    [No Abstract]   [Full Text] [Related]  

  • 22. Expression of vascular endothelial growth factor in von Hippel-Lindau syndrome-associated papillary cystadenoma of the epididymis.
    Leung SY; Chan AS; Wong MP; Yuen ST; Fan YW; Chung LP
    Hum Pathol; 1998 Nov; 29(11):1322-4. PubMed ID: 9824115
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A variety of phenotype with R161Q germline mutation of the von Hippel-Lindau tumor suppressor gene in Japanese kindred.
    Iida K; Okimura Y; Takahashi K; Inomata S; Iguchi G; Kaji H; Chihara K
    Int J Mol Med; 2004 Mar; 13(3):401-4. PubMed ID: 14767570
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Germline mutation profile of the VHL gene in von Hippel-Lindau disease and in sporadic hemangioblastoma.
    Olschwang S; Richard S; Boisson C; Giraud S; Laurent-Puig P; Resche F; Thomas G
    Hum Mutat; 1998; 12(6):424-30. PubMed ID: 9829912
    [TBL] [Abstract][Full Text] [Related]  

  • 25. von Hippel-Lindau disease.
    Couch V; Lindor NM; Karnes PS; Michels VV
    Mayo Clin Proc; 2000 Mar; 75(3):265-72. PubMed ID: 10725953
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Putative control of angiogenesis in hemangioblastomas by the von Hippel-Lindau tumor suppressor gene.
    Stratmann R; Krieg M; Haas R; Plate KH
    J Neuropathol Exp Neurol; 1997 Nov; 56(11):1242-52. PubMed ID: 9370235
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Von Hippel-Lindau disease and central nervous system hemangioblastoma. Progress in genetics and clinical management].
    Richard S; Martin S; David P; Decq P
    Neurochirurgie; 1998 Nov; 44(4):258-66. PubMed ID: 9864697
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Germline mutation of von Hippel-Lindau (VHL) gene 695 G>A (R161Q) in a patient with a peculiar phenotype with type 2C VHL syndrome.
    Santarpia L; Lapa D; Benvenga S
    Ann N Y Acad Sci; 2006 Aug; 1073():198-202. PubMed ID: 17102087
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genotype-phenotype correlations in families with deletions in the von Hippel-Lindau (VHL) gene.
    Hes F; Zewald R; Peeters T; Sijmons R; Links T; Verheij J; Matthijs G; Leguis E; Mortier G; van der Torren K; Rosman M; Lips C; Pearson P; van der Luijt R
    Hum Genet; 2000 Apr; 106(4):425-31. PubMed ID: 10830910
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High frequency loss of heterozygosity in von Hippel-Lindau (VHL)-associated and sporadic pancreatic islet cell tumors: evidence for a stepwise mechanism for malignant conversion in VHL tumorigenesis.
    Lott ST; Chandler DS; Curley SA; Foster CJ; El-Naggar A; Frazier M; Strong LC; Lovell M; Killary AM
    Cancer Res; 2002 Apr; 62(7):1952-5. PubMed ID: 11929809
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression pattern of the von Hippel-Lindau protein in human tissues.
    Los M; Jansen GH; Kaelin WG; Lips CJ; Blijham GH; Voest EE
    Lab Invest; 1996 Aug; 75(2):231-8. PubMed ID: 8765323
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Von Hippel-Lindau disease].
    Shuin T; Ashida S; Yao M; Kanno H
    Nihon Rinsho; 2000 Jul; 58(7):1448-54. PubMed ID: 10921322
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reconsideration of biallelic inactivation of the VHL tumour suppressor gene in hemangioblastomas of the central nervous system.
    Gläsker S; Bender BU; Apel TW; van Velthoven V; Mulligan LM; Zentner J; Neumann HP
    J Neurol Neurosurg Psychiatry; 2001 May; 70(5):644-8. PubMed ID: 11309459
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas.
    Wizigmann-Voos S; Breier G; Risau W; Plate KH
    Cancer Res; 1995 Mar; 55(6):1358-64. PubMed ID: 7533661
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stromal cell-derived factor-1alpha and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor.
    Zagzag D; Krishnamachary B; Yee H; Okuyama H; Chiriboga L; Ali MA; Melamed J; Semenza GL
    Cancer Res; 2005 Jul; 65(14):6178-88. PubMed ID: 16024619
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of von hippel-lindau mutations with comparative genomic hybridization in sporadic and hereditary hemangioblastomas: possible genetic heterogeneity.
    Gijtenbeek JM; Jacobs B; Sprenger SH; Eleveld MJ; van Kessel AG; Kros JM; Sciot R; van Calenbergh F; Wesseling P; Jeuken JW
    J Neurosurg; 2002 Oct; 97(4):977-82. PubMed ID: 12405390
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The von Hippel-Lindau tumor suppressor gene. A rare and intriguing disease opening new insight into basic mechanisms of carcinogenesis.
    Decker HJ; Weidt EJ; Brieger J
    Cancer Genet Cytogenet; 1997 Jan; 93(1):74-83. PubMed ID: 9062583
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Von Hippel-Lindau gene alterations in sporadic benign and malignant pheochromocytomas.
    Dannenberg H; De Krijger RR; van der Harst E; Abbou M; IJzendoorn Y; Komminoth P; Dinjens WN
    Int J Cancer; 2003 Jun; 105(2):190-5. PubMed ID: 12673678
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic study of a large Chinese kindred with von Hippel-Lindau disease.
    Huang YR; Zhang J; Wang JD; Fan XD
    Chin Med J (Engl); 2004 Apr; 117(4):552-7. PubMed ID: 15109448
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.